bioRxivBiochemistry
Cyclic gallium-68 labeled peptides for specific detection of human angiotensin-converting enzyme 2
M. Parker, J. Blecha, O. Rosenberg, M. Ohliger, R. Flavell, D. M. Wilson
Abstract
In this study, we developed ACE2-specific, peptide-derived 68Ga-labeled radiotracers, motivated by the hypotheses that (1) ACE2 is an important determinant of SARS-CoV-2 susceptibility, and (2) that modulation of ACE2 in COVID-19 drives severe organ injury. MethodsA series of NOTA-conjugated peptides derived from the known ACE2 inhibitor DX600 were synthesized, with variable linker identity. Since DX600 bears two cystine residues, both linear and cyclic peptides were studied. An ACE2 inhibition assay was used to identify lead compounds, which were labeled with 68Ga to generate peptide radiotracers ([68Ga]NOTA-PEP). The aminocaproate-derived radiotracer [68Ga]NOTA-PEP4 was subsequently studied in a humanized ACE2 (hACE2) transgenic model. ResultsCyclic DX-600 derived peptides had markedly lower IC50s than their linear counterparts. The three cyclic peptides with triglycine, aminocaproate, and polyethylene glycol linkers had calculated IC50s similar to, or lower than the parent DX600 molecule. Peptides were readily labeled with 68Ga, and the biodistribution of [68Ga]NOTA-PEP4 was determined in a hACE2 transgenic murine cohort. Pharmacologic concentrations of co-administered NOTA-PEP ("blocking") showed significant reduction of [68Ga]NOTA-PEP4 signals in the in the heart, liver, lungs, and small intestine. Ex vivo hACE2 activity in these organs was confirmed as a correlate to in vivo results. ConclusionsNOTA-conjugated, cyclic peptides derived from the known ACE2 inhibitor DX600 retain their activity when N-conjugated for 68Ga chelation. In vivo studies in a transgenic hACE2 murine model using the lead tracer [68Ga]NOTA-PEP4 showed specific binding in the heart, liver, lungs and intestine - organs known to be affected in SARS-CoV-2 infection. These results suggest that [68Ga]NOTA-PEP4 could be used to detect organ-specific suppression of ACE2 in SARS-CoV-2 infected murine models and COVID-19 patients. TOC figure O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=44 SRC="FIGDIR/small/412809v1_ufig1.gif" ALT="Figure 1"> View larger version (18K): org.highwire.dtl.DTLVardef@f3047org.highwire.dtl.DTLVardef@12ab9a9org.highwire.dtl.DTLVardef@33f43org.highwire.dtl.DTLVardef@12e77ed_HPS_FORMAT_FIGEXP M_FIG For Table of Contents use only C_FIG
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Development and structure-guided characterization of a novel ACE2-binding macrocyclic peptide
Roger Benoit, Jinling Wang, … Jeffrey W. Bode·Journal of Structural Biology XPeer-reviewed·Apr 23, 2026
- Stapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro
F. Curreli, S. M. B. Victor, … A. K. Debnath·bioRxiv·Aug 25, 2020
- Angiotensin peptides enhance SARS-CoV-2 spike protein binding to its host cell receptors
Katelin X. Oliveira, Yuichiro Suzuki·bioRxiv·Dec 12, 2024
- Development of radiofluorinated MLN-4760 derivatives for PET imaging of the SARS-CoV-2 entry receptor ACE2
Jinling Wang, Darja Beyer, … Cristina Müller·European Journal of Nuclear Medicine and Molecular ImagingPeer-reviewed·Jul 27, 2024
- Mechanism of ligand recognition by human ACE2 receptor
A. Bhattarai, S. Pawnikar, Y. Miao·bioRxiv·Oct 30, 2020
- A collection of designed peptides to target SARS-Cov-2 - ACE2 interaction: PepI-Covid19 database.
Rubén Molina-Fernández, Baldomero Oliva, Narcís Fernández‐Fuentes·bioRxiv·Apr 28, 2020